[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

  • Product portfolio
  • Potentially strong market reviews
  • Competitive analytics
  • Prospect partners
  • Mergers and acquisitions project data
  • Latest trends across a particular industry area
  • Research and development strategies
  • The analysis of new customers
  • A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 3,647
Sort by:
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drugs in Development, 2021 US$ 3,000.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development ...

April 2021 60 pages
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Drugs in Development, 2021 US$ 3,000.00

... players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) development ...

April 2021 35 pages
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drugs in Development, 2021 US$ 3,000.00

... and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and ...

April 2021 75 pages
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drugs in Development, 2021 US$ 3,000.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) development ...

April 2021 45 pages
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drugs in Development, 2021 US$ 3,000.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development ...

April 2021 65 pages
1 Phosphatidylinositol 3 Phosphate 5 Kinase (FYVE Finger Containing Phosphoinositide Kinase or Phosphatidylinositol 3 Phosphate 5 Kinase Type III or PIKFYVE or EC 2.7.1.150) - Drugs in Development, 2021 US$ 3,000.00

1 Phosphatidylinositol 3 Phosphate 5 Kinase (FYVE Finger Containing Phosphoinositide Kinase or Phosphatidylinositol 3 Phosphate 5 Kinase Type III or PIKFYVE or EC 2.7.1.150) - Drugs in Development, 20...

April 2021 35 pages
1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021 US$ 3,000.00

1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021 SUMMARY 1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021 provides in depth analysis on 1,3 Beta Glucan Synthase (...

April 2021 30 pages
16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 US$ 3,000.00

16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 SUMMARY 16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 provides in depth analysis on 16S Ribosomal RNA (16S rRNA) targeted pipeline...

April 2021 85 pages
23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 US$ 3,000.00

23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 SUMMARY 23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 provides in depth analysis on 23S Ribosomal RNA (23S rRNA) targeted pipeline...

April 2021 70 pages
3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) - Drugs in Development, 2021 US$ 3,000.00

3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) - Drugs in Development, 2021 SUMMARY 3 Hydroxy 3 Methylglutaryl Coenz...

April 2021 80 pages
3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 (5 Alpha SR2 or Steroid 5 Alpha Reductase 2 or Type II 5 Alpha Reductase or SR Type 2 or SRD5A2 or EC 1.3.1.22) - Drugs in Development, 2021 US$ 3,000.00

3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 (5 Alpha SR2 or Steroid 5 Alpha Reductase 2 or Type II 5 Alpha Reductase or SR Type 2 or SRD5A2 or EC 1.3.1.22) - Drugs in Development, 2021 SUMMARY 3-Oxo 5-Alp...

April 2021 35 pages
30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021 US$ 3,000.00

30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021 SUMMARY 30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021 provides in depth analysis on 30S Ribosomal Subunit (30S RNA) targeted...

April 2021 40 pages
3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021 US$ 3,000.00

3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021 SUMMARY 3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021 provides in depth analysis on 3C...

April 2021 60 pages
5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1...

April 2021 115 pages
5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or Serotonin 1D Beta Receptor or Serotonin Receptor 1B or HTR1B) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or Serotonin 1D Beta Receptor or Serotonin Receptor 1B or HTR1B) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or S...

April 2021 55 pages
5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D A...

April 2021 60 pages
5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021 provides in depth anal...

April 2021 45 pages
5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in De...

April 2021 170 pages
5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxyt...

April 2021 50 pages
5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021 provid...

April 2021 60 pages
5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Developmen...

April 2021 40 pages
5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Deve...

April 2021 40 pages
50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021 US$ 3,000.00

50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021 SUMMARY 50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021 provides in depth analysis on 50S Ribosomal Subunit (50S RNA) targeted...

April 2021 30 pages
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021 US$ 3,000.00

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021 SUMMARY 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021 provides in dept...

April 2021 35 pages
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Drugs in Development, 2021 US$ 3,000.00

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Drugs in Developme...

April 2021 30 pages
Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Drugs in Development, 2021 US$ 3,000.00

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Drugs in Development, 2021 SUMMARY Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14)...

April 2021 30 pages
Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in Development, 2021 US$ 3,000.00

Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in Development, 2021 SUMMARY Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in...

April 2021 30 pages
Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) - Drugs in Development, 2021 US$ 3,000.00

Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) - Drugs in Development, 2021 SUMMARY Acetylcholinesterase (Acetylcholin...

April 2021 105 pages
Achromatopsia (Genetic Disorders) - Drugs in Development, 2021 US$ 2,000.00

Achromatopsia (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Achromatopsia (Genetic Disorders) - Drugs in Development, 2021 provides an overview of the Achromatopsia pipeline landscape. The...

April 2021 30 pages
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorders) - Drugs in Development, 2021 US$ 2,000.00

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorder...

April 2021 35 pages
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorders) - Drugs in Development, 2021 US$ 2,000.00

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorder...

April 2021 35 pages
Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021 US$ 2,000.00

Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021 SUMMARY Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021 prov...

April 2021 50 pages
Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021 US$ 2,000.00

Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021 SUMMARY Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021 provides an overview of the Acral Lentiginous Melanoma pip...

April 2021 30 pages
Acute Bronchitis (Respiratory) - Drugs in Development, 2021 US$ 2,000.00

Acute Bronchitis (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Bronchitis (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Bronchitis pipeline landscape. The rep...

April 2021 30 pages
Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021 US$ 2,000.00

Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021 SUMMARY Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Acute Coronary Syndrome...

April 2021 50 pages
Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021 US$ 2,000.00

Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021 SUMMARY Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Acute Heart Failure pipeline lan...

April 2021 50 pages
Acute Inflammation (Immunology) - Drugs in Development, 2021 US$ 2,000.00

Acute Inflammation (Immunology) - Drugs in Development, 2021 SUMMARY Acute Inflammation (Immunology) - Drugs in Development, 2021 provides an overview of the Acute Inflammation pipeline landscape. The...

April 2021 45 pages
Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021 US$ 2,000.00

Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021 SUMMARY Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Acute Ischem...

April 2021 125 pages
Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 US$ 2,000.00

Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Acute Liver Failure pipeline...

April 2021 45 pages
Acute Lung Injury (Respiratory) - Drugs in Development, 2021 US$ 2,000.00

Acute Lung Injury (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Lung Injury (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Lung Injury pipeline landscape. The...

April 2021 115 pages
Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 US$ 2,000.00

Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 SUMMARY Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Acute Lymphoblastic Lympho...

April 2021 45 pages
Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 US$ 2,000.00

Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 SUMMARY Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 provides an overview of the Acute Opioid Overdosage pipeline...

April 2021 40 pages
Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 US$ 2,000.00

Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the Acute Promyelocytic Leukem...

April 2021 35 pages
Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 US$ 2,000.00

Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Respiratory Failure...

April 2021 30 pages
Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 US$ 2,000.00

Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 SUMMARY Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 provides an...

April 2021 45 pages
Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 US$ 2,000.00

Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 SUMMARY Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Acute...

April 2021 35 pages
Addiction (Central Nervous System) - Drugs in Development, 2021 US$ 2,000.00

Addiction (Central Nervous System) - Drugs in Development, 2021 SUMMARY Addiction (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Addiction pipeline landscape. The re...

April 2021 45 pages
Adenocarcinoma Of The Gastroesophageal Junction (Oncology) - Drugs in Development, 2021 US$ 2,500.00

Adenocarcinoma Of The Gastroesophageal Junction (Oncology) - Drugs in Development, 2021 SUMMARY Adenocarcinoma Of The Gastroesophageal Junction (Oncology) - Drugs in Development, 2021 provides an over...

April 2021 260 pages
Adenocarcinoma (Oncology) - Drugs in Development, 2021 US$ 2,000.00

Adenocarcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Adenocarcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Adenocarcinoma pipeline landscape. The report provides...

April 2021 100 pages
Adenoid Cystic Carcinoma (ACC) (Oncology) - Drugs in Development, 2021 US$ 2,000.00

Adenoid Cystic Carcinoma (ACC) (Oncology) - Drugs in Development, 2021 SUMMARY Adenoid Cystic Carcinoma (ACC) (Oncology) - Drugs in Development, 2021 provides an overview of the Adenoid Cystic Carcino...

April 2021 60 pages

Filters

Search

Categories

1,476
1,492
126
9
6
1
1
1
4
522
3
6

Publishers

3,647

Regions

3,647

Price

Date

Pages

Offers